Onkologie. 2014:8(1):42-43
Bevacizumab in Treatment of Metastatic Breast Cancer
- Komplexní onkologické centrum, Krajská nemocnice Liberec, Oddělení klinické onkologie
Metastatic breast cancer is incurable disease, but application of new therapeutic options reduce complaint of patient, extend time to
progression and extend overall survival. Treatment of chemotherapy is often concomitant with undesirabels effects and during of the treatment
come to pass chemoresistance. New chance of treatment is combination of chemotherapy with targeted treatment. The vascular
endothelial growth factor (VEGF) is the main regulator of angiogenesis. The humanized monoclonal antibody antiVEGF – bevacizumab –
evidenced efficiency in series cancer diseases. The case report presents a our experience of the combined treatment of bevacizumab
with chemotherapy at patient with chemoresistant triple negative breast cancer.
Keywords: metastatic breast cancer, angiogenesis, antiangiogenic therapy, bevacizumab
Published: March 1, 2014 Show citation
References
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
Go to original source... 
Go to PubMed... - Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18(7): 1423-1431. Go to original source... Go to PubMed...
- Gray-Robert, Bhattacharya-Suman, Bowden-Christopher, Miller-Kathy, Comis-Robert-L. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol. 2009; 27(30): 4966-4972. Go to original source... Go to PubMed...
- Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2010; 28(20): 3239-3247. Go to original source... Go to PubMed...
- Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29(10): 1252-1260. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7. Go to original source... Go to PubMed...
- O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). 2010 ASCO Annual Meeting - Citation: J Clin Oncol 28:7s, 2010(suppl; abstr 1005). Go to original source...
- Miles DW, Romieu G, Dieras V, Chen D, Duenne A, O'Shaughnessy J. Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (bv) and first-line chemotherapy as treatment for metastatic breast cancer (MBC). Annals of Oncology, vol. 21, 2010, suppl 8: Abstract Book of the 35th ESMO Congress, abstract 279PD.
- O'Shaughnessy J, Romieu G, Diéras V, Byrtek M, Duenne A-A, Miles D. Meta-Analysis of Patients with Triple-Negative Disease from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Metastatic Breast Cancer (MBC). San Antonio Breast Cancer Symposium 2010, abstract P6-12-03. Go to original source...